Cancer Letters
Volume 241, Issue 1 , Pages 142-149 , 8 September 2006

Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours

  • Charlotta Ryk

      Affiliations

    • Department of Biosciences at Novum, Karolinska Institute, 141 57 Huddinge, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 8 6089253; fax: +46 8 6081501.
    • ,
  • Rajiv Kumar

      Affiliations

    • Department of Biosciences at Novum, Karolinska Institute, 141 57 Huddinge, Sweden
    • Division of Molecular Genetic Epidemiology, German Cancer Research Center, 69120 Heidelberg, Germany
    • ,
  • Somali Sanyal

      Affiliations

    • Department of Biosciences at Novum, Karolinska Institute, 141 57 Huddinge, Sweden
    • Department of Oncology-Pathology, Clinical Cancer Epidemiology and Clinical Oncology, Karolinska Hospital, 171 76 Stockholm, Sweden
    • ,
  • Petra J. Berggren de Verdier

      Affiliations

    • Department of Oncology-Pathology, Clinical Cancer Epidemiology and Clinical Oncology, Karolinska Hospital, 171 76 Stockholm, Sweden
    • Department of Molecular Medicine and Surgery, Karolinska Institute, M3:02, 171 76 Stockholm, Sweden
    • ,
  • Kari Hemminki

      Affiliations

    • Department of Biosciences at Novum, Karolinska Institute, 141 57 Huddinge, Sweden
    • Division of Molecular Genetic Epidemiology, German Cancer Research Center, 69120 Heidelberg, Germany
    • ,
  • Per Larsson

      Affiliations

    • Department of Oncology-Pathology, Clinical Cancer Epidemiology and Clinical Oncology, Karolinska Hospital, 171 76 Stockholm, Sweden
    • Department of Urology, Karolinska hospital, 171 76 Stockholm, Sweden
    • ,
  • Gunnar Steineck

      Affiliations

    • Department of Oncology-Pathology, Clinical Cancer Epidemiology and Clinical Oncology, Karolinska Hospital, 171 76 Stockholm, Sweden
    • ,
  • Sai-Mei Hou

      Affiliations

    • Department of Biosciences at Novum, Karolinska Institute, 141 57 Huddinge, Sweden

Received 6 June 2005 ,Revised 8 October 2005 ,Accepted 12 October 2005.

References 

  1. Knowles MA. Identification of novel bladder tumour suppressor genes. Electrophoresis. 1999;20:269–279
  2. Knowles MA. The genetics of transitional cell carcinoma: progress and potential clinical application. Br. J. Urol. Int. 1999;84:412–427
  3. Hainaut P, Pfeifer GP. Patterns of p53 G—>T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis. 2001;22:367–374
  4. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics. 1998;8:27–31
  5. Hussain SP, Harris CC. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat. Res. 1999;428:23–32
  6. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, et al. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res. 1994;54:1551–1555
  7. Ryk C, Berggren P, Kumar R, Hemminki K, Larsson P, Steineck G, et al. Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int. J. Cancer. 2005;113:761–768
  8. Benhamou S, Sarasin A. Variability in nucleotide excision repair and cancer risk: a review. Mutat. Res. 2000;462:149–158
  9. Larsson P, Wijkstrom H, Thorstenson A, Adolfsson J, Norming U, Wiklund P, et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand. J. Urol. Nephrol. 2003;37:195–201
  10. Sambrook J, Fritsch E, Maniatis T. Molecular Cloning. A Laboratory Manual. New York: Cold Spring Harbour; 1989;
  11. Hall RR, Prout GR. Staging of bladder cancer: is the tumor, node, metastasis system adequate?. Semin. Oncol. 1990;17:517–523
  12. Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years.. Acta Chir. Scand. 1965;300:371–378
  13. Wada T, Louhelainen J, Hemminki K, Adolfsson J, Wijkstrom H, Norming U, et al. Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade. Clin. Cancer Res. 2000;6:610–615
  14. Berggren P, Steineck G, Hemminki K. A rapid fluorescence based multiplex polymerase chain reaction–single-strand conformation polymorphism method for p53 mutation detection. Electrophoresis. 2000;21:2335–2342
  15. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–734
  16. Hou SM, Falt S, Angelini S, Yang K, Nyberg F, Lambert B, et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis. 2002;23:599–603
  17. Brockmöller J, Kaiser R, Kerb R, Cascorbi I, Jaeger V, Roots I. Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. Pharmacogenetics. 1996;535–545
  18. Berggren P, Steineck G, Adolfsson J, Hansson J, Jansson O, Larsson P, et al. p53 mutations in urinary bladder cancer. Br. J. Cancer. 2001;84:1505–1511
  19. Hou SM, Ryk C, Kannio A, Angelini S, Falt S, Nyberg F, et al. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors. Environ. Mol. Mutagen. 2003;41:37–42
  20. Hsieh LL, Chien HT, Chen IH, Liao CT, Wang HM, Jung SM, et al. The XRCC1 399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. Cancer Epidemiol. Biomarkers Prev. 2003;12:439–443
  21. Medina PP, Ahrendt SA, Pollan M, Fernandez P, Sidransky D, Sanchez-Cespedes M. Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations. Cancer Epidemiol. Biomarkers Prev. 2003;12:699–704
  22. Gao WM, Romkes M, Day RD, Siegfried JM, Luketich JD, Mady HH, et al. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis. 2003;24:1671–1676
  23. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2001;2:731–737
  24. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–707
  25. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677
  26. Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H, et al. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene. 1998;16:1701–1712
  27. Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257–264
  28. Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC. A case-control study of cyclin D1 CCND1 870A—>G polymorphism and bladder cancer. Carcinogenesis. 2003;24:1645–1650
  29. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis. 2001;22:1437–1445
  30. Vineis P, Martone T. Genetic-environmental interactions and low-level exposure to carcinogens. Epidemiology. 1995;6:455–457
  31. Hanawalt PC, Ford JM, Lloyd DR. Functional characterization of global genomic DNA repair and its implications for cancer. Mutat. Res. 2003;544:107–114
  32. Adimoolam S, Ford JM. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc. Natl Acad. Sci. USA. 2002;99:12985–12990
  33. Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet. Med. 2002;4:62–70
  34. Ross D, Traver RD, Siegel D, Kuehl BL, Misra V, Rauth AM. A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br. J. Cancer. 1996;74:995–996
  35. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype–phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999;9:113–121
  36. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992;52:797–802
  37. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004;25:973–978
  38. Schulz WA, Krummeck A, Rosinger I, Eickelmann P, Neuhaus C, Ebert T, et al. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 1997;7:235–239
  39. Sekiguchi M, Tsuzuki T. Oxidative nucleotide damage: consequences and prevention. Oncogene. 2002;21:8895–8904

PII: S0304-3835(05)00943-2

doi: 10.1016/j.canlet.2005.10.025

Cancer Letters
Volume 241, Issue 1 , Pages 142-149 , 8 September 2006

Article Tools